In MM-6 cells, Bindarit inhibited MCP-1 with an IC50 of 250 ± 60 μM and did not change basal cytokine expression in unstimulated cells. In mouse brain-derived microglia, Bindarit at 50 μM for 4 hr reduced basal CCL2 mRNA by nearly 75%. In rat VSMCs, Bindarit at 100 and 300 µM significantly inhibited PDGF-BB-induced proliferation by 27% and 42%, respectively, compared with PDGF-BB controls. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Bindarit inhibits release of MCP-1 from LPS-stimulated MM-6 cells
Cell-based study · MM-6 cells [1]
In preliminary experiments, the IC50 of bindarit was 250 ± 60 μM. In unstimulated cells, bindarit alone did not change the basal expression of the two cytokines.
Literature-Reported Treatment Conditions
- Reported limits
- Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations
Compound reported in the paper: Bindarit
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Bindarit differentially regulates LPS-mediated secretion of IL-8 and MCP-1 (S2, S3, S5)
inhibition of MCP-1: inhibition of MCP-1 — Results > Bindarit differentially regulates LPS-mediated secretion of IL-8 and MCP-1 (S3, S5)
Bindarit suppresses basal CCL2 expression in mouse microglia
Cell-based study · Microglia, prepared from C57BL/6 mouse brain [2]
Microglia prepared from C57BL/6 mouse brain were incubated with Bindarit at 50 μM for 4 hr. Basal CCL2 mRNA was reduced by nearly 75%.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 μM
- Exposure duration
- 4 hr
- Method
- incubated with bindarit
- Vehicle
- dimethyl sulfoxide (DMSO)
Methods and source locations
Compound reported in the paper: Bindarit
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Preparation of bindarit (S4); Results > Bindarit differentially suppresses CCL2 expression by cultured CNS cells (S75); Figure 1 legend (S117, S118, S119)
Relative CCL2 RNA levels were determined by qRT-PCR: Relative CCL2 RNA levels were determined by qRT-PCR; comparator: Control cultures received only vehicle. — Results > Bindarit differentially suppresses CCL2 expression by cultured CNS cells (S75); Figure 1 legend (S119)
Bindarit inhibits PDGF-BB-induced rat vascular smooth muscle cell proliferation
Cell-based study · rat VSMCs [3]
Rat VSMCs were incubated with Bindarit in medium containing PDGF-BB. Bindarit at 100 and 300 µM significantly inhibited PDGF-BB-induced proliferation by 27% and 42%, respectively, compared with PDGF-BB alone.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10–300 µM
- Exposure duration
- 48 h
- Method
- incubated with DMEM containing PDGF-BB
- Co-treatment
- Other interventions in this design: PDGF-BB 10 ng/mL. Compound effect isolated by the comparison: vs. platelet derived growth factor-BB (PDGF-BB).
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Bindarit
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Enzyme-linked immunosorbent assay for MCP-1 protein (S10); Methods > Proliferation assay (S12, S13); Methods > Chemotactic migration and invasion (S18); Results > Effect of bindarit on rat VSMC proliferation and migration (S83); Figure 1 legend (S127)
cell proliferation assay: cell proliferation assay; comparator: PDGF-BB — Methods > Proliferation assay (S12); Results > Effect of bindarit on rat VSMC proliferation and migration (S83)